Skip to content

Vertex Pharmaceuticals

NASDAQ: VRTX · USD

Vertex Pharmaceuticals cash flow and EPS—

Operating cash flow, capital investment, free cash flow and earnings per share.

Capital allocation

% of tracked cash uses

$581.7M
Vertex Pharmaceuticals capital allocation. Quarterly values. Missing values are unavailable.
PeriodCapexAcquisitionsBuybacksDividendsDebt repaymentsTracked uses
FY 2010 Q1100% · $3.11MUnavailableUnavailableUnavailableUnavailable100% · $3.11M
FY 2010 Q2100% · $9.686MUnavailableUnavailableUnavailableUnavailable100% · $9.686M
FY 2010 Q3100% · $10.83MUnavailableUnavailableUnavailableUnavailable100% · $10.83M
FY 2010 Q4100% · $14.428MUnavailableUnavailableUnavailableUnavailable100% · $14.428M
FY 2011 Q18.84% · $4.85MUnavailableUnavailableUnavailable91.16% · $50M100% · $54.85M
FY 2011 Q2100% · $10.431MUnavailableUnavailableUnavailable0% · $0M100% · $10.431M
FY 2011 Q3100% · $9.985MUnavailableUnavailableUnavailable0% · $0M100% · $9.985M
FY 2011 Q48.16% · $9.329MUnavailableUnavailableUnavailable91.84% · $105M100% · $114.329M
FY 2012 Q1100% · $6.155MUnavailableUnavailableUnavailableUnavailable100% · $6.155M
FY 2012 Q2100% · $15.543MUnavailableUnavailableUnavailableUnavailable100% · $15.543M
FY 2012 Q3100% · $21.396MUnavailableUnavailableUnavailable0% · $0M100% · $21.396M
FY 2012 Q4100% · $28.046MUnavailableUnavailableUnavailableUnavailable100% · $28.046M
FY 2013 Q1100% · $16.607MUnavailableUnavailableUnavailableUnavailable100% · $16.607M
FY 2013 Q2100% · $1.801MUnavailableUnavailableUnavailableUnavailable100% · $1.801M
FY 2013 Q3100% · $18.514MUnavailableUnavailableUnavailable0% · $0M100% · $18.514M
FY 2013 Q4100% · $14.471MUnavailableUnavailableUnavailableUnavailable100% · $14.471M
FY 2014 Q1100% · $15.526MUnavailableUnavailableUnavailableUnavailable100% · $15.526M
FY 2014 Q2100% · $11.701MUnavailableUnavailableUnavailableUnavailable100% · $11.701M
FY 2014 Q3100% · $9.298MUnavailableUnavailableUnavailable0% · $0M100% · $9.298M
FY 2014 Q4100% · $14.676MUnavailableUnavailableUnavailableUnavailable100% · $14.676M
FY 2015 Q1100% · $10.558MUnavailableUnavailableUnavailableUnavailable100% · $10.558M
FY 2015 Q2100% · $13.42MUnavailableUnavailableUnavailableUnavailable100% · $13.42M
FY 2015 Q3100% · $8.797MUnavailableUnavailableUnavailableUnavailable100% · $8.797M
FY 2015 Q4100% · $12.527MUnavailableUnavailableUnavailableUnavailable100% · $12.527M
FY 2016 Q1100% · $11.974MUnavailableUnavailableUnavailableUnavailable100% · $11.974M
FY 2016 Q2100% · $15.918MUnavailableUnavailableUnavailableUnavailable100% · $15.918M
FY 2016 Q3100% · $13.883MUnavailableUnavailableUnavailableUnavailable100% · $13.883M
FY 2016 Q4100% · $14.788MUnavailableUnavailableUnavailableUnavailable100% · $14.788M
FY 2017 Q1100% · $11.159MUnavailable0% · $0MUnavailableUnavailable100% · $11.159M
FY 2017 Q2100% · $17.707MUnavailable0% · $0MUnavailableUnavailable100% · $17.707M
FY 2017 Q3100% · $27.951MUnavailable0% · $0MUnavailableUnavailable100% · $27.951M
FY 2017 Q4100% · $42.604MUnavailable0% · $0MUnavailableUnavailable100% · $42.604M
FY 2018 Q174.54% · $29.279MUnavailable25.46% · $10MUnavailableUnavailable100% · $39.279M
FY 2018 Q221.99% · $29.612MUnavailable78.01% · $105.033MUnavailableUnavailable100% · $134.645M
FY 2018 Q318.52% · $20.912MUnavailable81.48% · $92.005MUnavailableUnavailable100% · $112.917M
FY 2018 Q49.9% · $15.721M0% · $0M90.1% · $143.005MUnavailableUnavailable100% · $158.726M
FY 2019 Q115.3% · $18.041MUnavailable84.7% · $99.839MUnavailableUnavailable100% · $117.88M
FY 2019 Q222.6% · $16.358MUnavailable77.4% · $56.01MUnavailableUnavailable100% · $72.368M
FY 2019 Q399.57% · $24.291MUnavailable0.43% · $0.104MUnavailableUnavailable100% · $24.395M
FY 2019 Q41.74% · $16.761M94.5% · $908.388M3.75% · $36.062MUnavailableUnavailable100% · $961.211M
FY 2020 Q16.09% · $19.45MUnavailable93.91% · $300.026MUnavailableUnavailable100% · $319.476M
FY 2020 Q2100% · $17.864MUnavailable0% · $0MUnavailableUnavailable100% · $17.864M
FY 2020 Q361.81% · $174.795MUnavailable38.19% · $108.007MUnavailableUnavailable100% · $282.802M
FY 2020 Q426.67% · $47.689M0% · $0M73.33% · $131.103MUnavailableUnavailable100% · $178.792M
FY 2021 Q114.3% · $70.926MUnavailable85.7% · $424.952MUnavailableUnavailable100% · $495.878M
FY 2021 Q2100% · $49.837MUnavailable0% · $0MUnavailableUnavailable100% · $49.837M
FY 2021 Q37.67% · $52.522MUnavailable92.33% · $632.273MUnavailableUnavailable100% · $684.795M
FY 2021 Q414.36% · $61.715M0% · $0M85.64% · $368.175MUnavailableUnavailable100% · $429.89M
FY 2022 Q1100% · $63.6MUnavailable0% · $0MUnavailableUnavailable100% · $63.6M
FY 2022 Q2100% · $53.3MUnavailable0% · $0MUnavailableUnavailable100% · $53.3M
FY 2022 Q3100% · $54.2MUnavailable0% · $0MUnavailableUnavailable100% · $54.2M
FY 2022 Q4100% · $33.6M0% · $0M0% · $0MUnavailableUnavailable100% · $33.6M
FY 2023 Q124.07% · $42.1MUnavailable75.93% · $132.8MUnavailableUnavailable100% · $174.9M
FY 2023 Q267.8% · $59.6MUnavailable32.2% · $28.3MUnavailableUnavailable100% · $87.9M
FY 2023 Q325.76% · $40.6MUnavailable74.24% · $117MUnavailableUnavailable100% · $157.6M
FY 2023 Q427.99% · $58.1M0% · $0M72.01% · $149.5MUnavailableUnavailable100% · $207.6M
FY 2024 Q134.27% · $68.4MUnavailable65.73% · $131.2MUnavailableUnavailable100% · $199.6M
FY 2024 Q217.72% · $69MUnavailable82.28% · $320.3MUnavailableUnavailable100% · $389.3M
FY 2024 Q318.03% · $67.7MUnavailable81.97% · $307.7MUnavailableUnavailable100% · $375.4M
FY 2024 Q418.14% · $92.6MUnavailable81.86% · $417.9MUnavailableUnavailable100% · $510.5M
FY 2025 Q18.72% · $40.7MUnavailable91.28% · $426.1MUnavailableUnavailable100% · $466.8M
FY 2025 Q227.11% · $145.7MUnavailable72.89% · $391.8MUnavailableUnavailable100% · $537.5M
FY 2025 Q38.68% · $101.8MUnavailable91.32% · $1,071.1MUnavailableUnavailable100% · $1,172.9M
FY 2025 Q453.78% · $149.4MUnavailable46.22% · $128.4MUnavailableUnavailable100% · $277.8M
FY 2026 Q128.36% · $133.4MUnavailable71.64% · $336.9MUnavailableUnavailable100% · $470.3M
FY 2026 Q219.29% · $112.2MUnavailable80.71% · $469.5MUnavailableUnavailable100% · $581.7M
Mar 31, 2010 through Jun 30, 2026

Operating cash flow

USD millions

$1,125.4M

Capital expenditures

USD millions

$112.2M

Free cash flow

USD millions

$1,013.2M

Stock-based compensation

USD millions

$170.2M

SBC / free cash flow

% · FCF before SBC deduction

16.8%

SBC / operating cash flow

%

15.12%

Software & intangible investment

USD millions

—

Separately disclosed software and intangible investment is unavailable in the extracted statements for this period.

Diluted EPS

USD per share

$4.31

Quarterly data

Vertex Pharmaceuticals cash-flow history. Each metric has its own unit. A dash means inputs are missing or the calculation is undefined.
Fiscal periodEndedOperating cash flowUSD millionsCapital expendituresUSD millionsFree cash flowUSD millionsStock-based compensationUSD millionsSBC / free cash flow%SBC / operating cash flow%Software & intangible investmentUSD millionsDiluted EPSUSD per share
FY 2026 Q2Jun 30, 20261,125.4112.21,013.2170.216.8%15.12%—$4.31
FY 2026 Q1Mar 31, 20261,428.1133.41,294.7166.412.85%11.65%—$4.02
FY 2025 Q4Dec 31, 2025498149.4348.6157.645.21%31.65%——
FY 2025 Q3Sep 30, 20251,241.4101.81,139.6194.917.1%15.7%—$4.2
FY 2025 Q2Jun 30, 20251,073.1145.7927.4167.318.04%15.59%—$3.99
FY 2025 Q1Mar 31, 2025818.940.7778.2166.121.34%20.28%—$2.49
FY 2024 Q4Dec 31, 2024584.692.6492167.834.11%28.7%——
FY 2024 Q3Sep 30, 20241,369.867.71,302.1184.614.18%13.48%—$4.01
FY 2024 Q2Jun 30, 2024-3,753.669-3,822.6154.2———$-13.92
FY 2024 Q1Mar 31, 20241,306.668.41,238.2191.915.5%14.69%—$4.21
FY 2023 Q4Dec 31, 2023234.658.1176.5208.6118.19%88.92%——
FY 2023 Q3Sep 30, 20231,268.440.61,227.8130.910.66%10.32%—$3.97
FY 2023 Q2Jun 30, 20231,134.459.61,074.8119.311.1%10.52%—$3.52
FY 2023 Q1Mar 31, 2023899.942.1857.8122.414.27%13.6%—$2.69
FY 2022 Q4Dec 31, 20221,078.433.61,044.8111.510.67%10.34%——
FY 2022 Q3Sep 30, 2022955.554.2901.3135.615.04%14.19%—$3.59
FY 2022 Q2Jun 30, 20221,139.853.31,086.5113.910.48%9.99%—$3.13
FY 2022 Q1Mar 31, 2022956.263.6892.6130.314.6%13.63%—$2.96
FY 2021 Q4Dec 31, 2021994.9961.72933.28118.6112.71%11.92%——
FY 2021 Q3Sep 30, 2021927.2252.52874.710311.78%11.11%—$3.28
FY 2021 Q2Jun 30, 2021-199.7749.84-249.6104.62———$0.26
FY 2021 Q1Mar 31, 2021921.0670.93850.13115.1713.55%12.5%—$2.49
FY 2020 Q4Dec 31, 2020491.5347.69443.8497.0321.86%19.74%—$2.3
FY 2020 Q3Sep 30, 2020907.75174.8732.9599.5413.58%10.97%—$2.53
FY 2020 Q2Jun 30, 20201,038.5317.861,020.66117.1911.48%11.28%—$3.18
FY 2020 Q1Mar 31, 2020815.719.45796.25115.7114.53%14.18%—$2.29
FY 2019 Q4Dec 31, 2019446.0116.76429.2591.5921.34%20.54%—$2.23
FY 2019 Q3Sep 30, 2019334.7924.29310.585.4227.51%25.51%—$0.22
FY 2019 Q2Jun 30, 2019463.7516.36447.3989.6920.05%19.34%—$1.03
FY 2019 Q1Mar 31, 2019324.7818.04306.7493.7930.58%28.88%—$1.03
FY 2018 Q4Dec 31, 2018314.5815.72298.8678.9426.41%25.09%—$5.97
FY 2018 Q3Sep 30, 2018381.3520.91360.4485.5323.73%22.43%—$0.5
FY 2018 Q2Jun 30, 2018321.729.61292.0982.4428.22%25.62%—$0.8
FY 2018 Q1Mar 31, 2018252.6629.28223.3878.1434.98%30.93%—$0.81
FY 2017 Q4Dec 31, 2017227.5142.6184.9175.440.78%33.14%—$0.39
FY 2017 Q3Sep 30, 2017170.0927.95142.1473.7751.9%43.37%—$-0.41
FY 2017 Q2Jun 30, 2017181.6517.71163.9572.5844.27%39.96%—$0.07
FY 2017 Q1Mar 31, 2017265.6911.16254.5368.9827.1%25.96%—$0.99
FY 2016 Q4Dec 31, 2016144.7214.79129.9459.0845.47%40.82%—$0.13
FY 2016 Q3Sep 30, 201665.6613.8851.7761.21118.23%93.23%—$-0.16
FY 2016 Q2Jun 30, 201640.8615.9224.9461.94248.34%151.6%—$-0.26
FY 2016 Q1Mar 31, 2016-15.1411.97-27.1155.47———$-0.17
FY 2015 Q4Dec 31, 2015-16.0112.53-28.5444.65———$-0.3
FY 2015 Q3Sep 30, 2015-47.028.8-55.8265.73———$-0.39
FY 2015 Q2Jun 30, 2015-95.2113.42-108.6363.26———$-0.78
FY 2015 Q1Mar 31, 2015-207.1810.56-217.7457.38———$-0.83
FY 2014 Q4Dec 31, 2014-121.8714.68-136.5542.38———$-0.74
FY 2014 Q3Sep 30, 2014-87.659.3-96.9546.14———$-0.72
FY 2014 Q2Jun 30, 2014-127.9211.7-139.6242.44———$-0.68
FY 2014 Q1Mar 31, 2014-175.7615.53-191.2946.58———$-1
FY 2013 Q4Dec 31, 201328.8614.4714.3823.37162.47%80.99%—$0.19
FY 2013 Q3Sep 30, 2013-13.7218.51-32.2331.31———$-0.54
FY 2013 Q2Jun 30, 2013-0.931.8-2.7341.35———$-0.26
FY 2013 Q1Mar 31, 2013-65.7816.61-82.3931.28———$-1.43
FY 2012 Q4Dec 31, 201240.5628.0512.5127.64220.86%68.14%—$-0.35
FY 2012 Q3Sep 30, 2012105.9621.484.5727.5832.62%26.03%—$-0.27
FY 2012 Q2Jun 30, 2012118.4115.54102.8631.3830.51%26.5%—$-0.31
FY 2012 Q1Mar 31, 20122.926.16-3.2427.69—949.52%—$0.43
FY 2011 Q4Dec 31, 2011503.669.33494.3329.055.88%5.77%—$0.74
FY 2011 Q3Sep 30, 201142.99.9932.9129.4189.38%68.57%—$1.02
FY 2011 Q2Jun 30, 2011-216.210.43-226.6331.88———$-0.85
FY 2011 Q1Mar 31, 2011-186.634.85-191.4827.88———$-0.87
FY 2010 Q4Dec 31, 2010-166.114.43-180.5323.57———$-0.9
FY 2010 Q3Sep 30, 2010-163.9910.83-174.8223.77———$-1.04
FY 2010 Q2Jun 30, 2010-108.899.69-118.5724.45———$-1
FY 2010 Q1Mar 31, 2010-196.463.11-199.5719.33———$-0.83
Sources and calculations

Financial inputs from company filings. Last checked Oct 18, 2026. A dash means missing inputs or an undefined calculation.

Period changes use the preceding fiscal quarter or year. Percentage changes divide by the absolute prior value; a zero or missing baseline has no percentage change. Percentage metrics show changes in percentage points.

FCF subtracts reported cash capital investment. PPE purchases are preferred; the productive-assets fallback also includes software and intangibles. Acquisitions and noncash lease additions are excluded. EPS and weighted shares are not summed across quarters. Annual figures use annual reports.

SBC / FCF always uses FCF before SBC deduction; both SBC ratios compare amounts from the same period. A zero or negative cash-flow denominator is undefined, and values above 100% are retained.

Each reported nonnegative cash use / sum of available tracked nonnegative cash uses × 100. Missing categories are omitted, never set to zero. This is the composition of tracked uses, not a complete cash-flow reconciliation or a percentage of OCF. SBC is noncash and excluded. Negative amounts are excluded as reversals or net receipts; they are not converted to spending. Annual bars use reported annual amounts. Turning off a category hides its share without changing the denominator. Debt repayments prefer a reported aggregate, with long-term or convertible-only scope identified in the tooltip. Acquisitions are net of cash acquired. Dividend payments use the aggregate where reported, including dividend equivalents when part of that concept.

The SBC option subtracts reported share-based compensation from FCF as an economic-cost scenario. Missing SBC never becomes zero.

Market prices: Yahoo Finance · VRTX, USD. Latest completed close Sep 25, 2026. Price data retrieved Sep 28, 2026.

Operating cash flow
Reported net cash provided by or used in operating activities.
Capital expenditures
Reported cash capital investment. Uses purchases of property, plant and equipment where disclosed; otherwise purchases of productive assets, which can also include software and intangibles. Excludes acquisitions and noncash lease additions.
Free cash flow
Operating cash flow − reported cash capital investment. PPE purchases are preferred; the productive-assets fallback also includes software and intangibles. Reflects the SBC option and can differ from issuer-defined FCF.
Stock-based compensation
Reported share-based compensation addback in the cash-flow statement. Missing disclosure is not treated as zero.
SBC / free cash flow
Reported share-based compensation / (operating cash flow − cash capital investment) × 100, for the same fiscal period. Always uses FCF before SBC deduction. Zero or negative FCF is undefined; values above 100% are retained.
SBC / operating cash flow
Reported share-based compensation / reported operating cash flow × 100, for the same fiscal period. Zero or negative operating cash flow is undefined. Unaffected by the SBC deduction scenario.
Software & intangible investment
Separately tagged payments for capitalized software under US GAAP, or purchases of intangible assets under IFRS. This optional disclosure is not inferred from total capex or deducted a second time from FCF.
Diluted EPS
Reported diluted earnings per share, normalized for recorded subsequent stock splits. Quarterly EPS is never subtracted from annual or YTD EPS.